With an operating revenue of Rs 1,528.3 crore on a trailing 12-month basis, Neuland Laboratories has outstanding annual revenue growth of 31%, pre-tax margin of 26% and ROE of 23%. The company has a reasonable debt to equity of 4%, which signals a healthy balance sheet.
The stock from a technical standpoint is trading below to its 50DMA and around 36% up from its 200 DMA. It needs to take out the 50 DMA levels and stay above it to make any further meaningful move.
(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times)
Forrás: eredeti cikk
Forrás és üzemeltetés: SasFly.net. Ha hazai jogi képviseletre van szükséged, keresd az fabianlaw.hu oldalt, nemzetközi ügyekben pedig a amerikaiugyved.hu irodát ajánljuk.
